Teckro, an NYC-based technology platform that makes the conduct of clinical trials simple, more transparent and more inclusive for doctors, research nurses and patients announced it has raised $25 million in funding. The Series C funding round was led by Northpond Ventures with participation from Founders Fund, Sands Capital Ventures, Bill Maris’ Section 32 venture fund, and Borealis Ventures. Teckro’s total funding now stands at $43 million.
Making Your Clinical Trial Information Instantly Accessible to Research Staff Globally
Founded by brothers Gary and Nigel Hughes and Jacek Skrzypiec in 2015., Teckro uses machine learning technologies to improve the speed and accuracy of clinical trials and works with the top pharmaceutical and biotech companies globally. The digital clinical trial platform makes it possible for all relevant information to be instantly accessible to every active member of a clinical trial and for the entire study teams to be connected effortlessly. This means drugs and treatments for the world’s most complex diseases are being developed quicker with the long-term goal of improving healthcare.
Recent Traction & Milestones
Teckro has users in over 80 countries, up from 30 countries at the time of the Series B in August 2017. It employs over 100 staff across its 3 global bases including its global headquarters in Limerick, Ireland, its engineering hub in Dublin, Ireland and its US base in Nashville, Tennessee.
There has been a 240% increase in the number of clinical trials on the Teckro platform over the past 12 months. The company plans to use the Series C round to continue its international expansion and product development in an effort to meaningfully impact and improve processes for all stakeholders involved in clinical trials.
“Despite all the talk of digital transformation, the actual experience of participating in a clinical trial if you are a doctor, research nurse or patient has changed little in the last 20 years. The industry still relies heavily on paper, on working off retrospective data, and there is still an over-reliance on sending CRAs to busy research sites. This approach, together with the plethora of point solutions that get ‘bolted on’, only adds to the complexity and disjointed experience of research sites and patients,” said CEO and founder Gary Hughes.
“Our vision is to be at the center of all site and patient interactions in a clinical trial. We are building new digital infrastructure and toolset for clinical research that makes the conduct of trials simpler, more transparent and more inclusive,” Huges added.
